OPS
AVTX icon

Orion Portfolio Solutions’s Avalo Therapeutics AVTX Stock Holding History

Orion Portfolio Solutions’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-9
Closed -$13K – 720
2022
Q2 		$13K Buy
+9
New +$12K ﹤0.01% 675

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Orion Portfolio Solutions's AVTX Position: Q3 2022 in Review

Orion Portfolio Solutions sold out of Avalo Therapeutics (AVTX) in Q3 2022, closing a stake of 9 shares — an estimated $13K sold.

Orion Portfolio Solutions first reported a position in AVTX in Q2 2022 and held it in 1 quarter. The position peaked at $13K in Q2 2022. 18 funds tracked by Wall St. Rank hold AVTX as of Q3 2022.

  • Orion Portfolio Solutions reported no remaining Avalo Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Orion Portfolio Solutions sold 9 Avalo Therapeutics shares in Q3 2022, an estimated $13K.
  • Orion Portfolio Solutions first reported a position in Avalo Therapeutics in Q2 2022 and held it in 1 quarter.
  • Orion Portfolio Solutions's Avalo Therapeutics position peaked at $13K in Q2 2022.
  • 18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2022.

Based on Orion Portfolio Solutions's 13F filing for Q3 2022, filed 9 Nov 2022.